📊 COEPW Key Takeaways
Is Coeptis Therapeutics Holdings, Inc. (COEPW) a Good Investment?
Coeptis Therapeutics is a pre-revenue biotech company with severe operational losses and negative cash burn that is unsustainable at current run rates. The company generated only $1.4M in revenue while burning $8.6M in operating cash flow, resulting in a -631% free cash flow margin with minimal runway based on $5.7M cash reserves. Despite strong balance sheet liquidity metrics, the company exhibits classic characteristics of a failing biotech venture with deteriorating fundamentals and no clear path to profitability.
Coeptis Therapeutics shows extremely weak core fundamentals: revenue is minimal relative to its cost base, operating losses are very large, and free cash flow is deeply negative. The balance sheet is currently supported by solid cash, low debt, and a strong current ratio, but without a major improvement in revenue scale or expense discipline, that liquidity cushion could erode quickly.
Why Buy Coeptis Therapeutics Holdings, Inc. Stock? COEPW Key Strengths
- Strong current ratio of 4.16x indicates short-term liquidity to meet immediate obligations
- Minimal debt burden with 0.01x debt-to-equity ratio providing financial flexibility
- High gross margin of 86.7% suggests strong unit economics if revenue scales, typical of biotech
- 9 Form 4 filings in last 90 days indicate insider engagement and activity
- Strong liquidity with $5.67M in cash and a 4.16x current ratio
- Very low leverage with only $150K of long-term debt and 0.01x debt-to-equity
- High gross margin of 86.7%, indicating favorable unit economics before overhead and corporate expenses
COEPW Stock Risks: Coeptis Therapeutics Holdings, Inc. Investment Risks
- Extreme cash burn of $8.6M annually against only $1.4M revenue is unsustainable; ~8 months of cash runway remaining
- Operating margin of -956.9% and net margin of -874.3% indicate massive losses with no near-term profitability path
- Minimal revenue generation suggests failed commercialization, late-stage development issues, or loss of market traction
- Negative ROE of -87.9% and ROA of -73.8% demonstrate value destruction for shareholders
- Pre-revenue biotech status with no clear pipeline success or upcoming catalyst visible in fundamentals
- Severe operating inefficiency, with operating margin at -956.9% and net margin at -874.3%
- Heavy cash burn, with operating cash flow and free cash flow both at -$8.60M
- Very small revenue base of $1.36M, raising concerns about scalability and sustainability of the business model
Key Metrics to Watch
- Operating cash flow trend and months of cash runway remaining
- Revenue growth trajectory and pipeline advancement milestones
- Quarterly cash burn rate changes and capital efficiency improvements
- Clinical trial progress and FDA approval status for key programs
- Working capital management and potential dilutive financing needs
- Operating cash burn relative to cash balance
- Revenue growth and operating loss reduction
Coeptis Therapeutics Holdings, Inc. (COEPW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.16x current ratio provides a solid financial cushion.
COEPW Profit Margin, ROE & Profitability Analysis
COEPW vs Finance Sector: How Coeptis Therapeutics Holdings, Inc. Compares
How Coeptis Therapeutics Holdings, Inc. compares to Finance sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Coeptis Therapeutics Holdings, Inc. Stock Overvalued? COEPW Valuation Analysis 2026
Based on fundamental analysis, Coeptis Therapeutics Holdings, Inc. has mixed fundamental signals relative to the Finance sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Coeptis Therapeutics Holdings, Inc. Balance Sheet: COEPW Debt, Cash & Liquidity
COEPW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Coeptis Therapeutics Holdings, Inc.'s revenue has grown significantly by 1,717% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.56 indicates the company is currently unprofitable.
COEPW Revenue Growth, EPS Growth & YoY Performance
COEPW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.8M | $-0.05 |
| Q2 2025 | N/A | -$3.0M | $-0.08 |
| Q1 2025 | N/A | -$3.0M | $-0.08 |
| Q3 2024 | N/A | -$1.8M | $-0.05 |
| Q2 2024 | N/A | -$3.0M | $-0.08 |
| Q1 2024 | N/A | -$3.0M | $-0.08 |
| Q3 2023 | N/A | -$3.1M | $-0.23 |
| Q2 2023 | N/A | -$3.1M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Coeptis Therapeutics Holdings, Inc. Dividends, Buybacks & Capital Allocation
COEPW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Coeptis Therapeutics Holdings, Inc. (CIK: 0001759186)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COEPW
What is the AI rating for COEPW?
Coeptis Therapeutics Holdings, Inc. (COEPW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COEPW's key strengths?
Claude: Strong current ratio of 4.16x indicates short-term liquidity to meet immediate obligations. Minimal debt burden with 0.01x debt-to-equity ratio providing financial flexibility. ChatGPT: Strong liquidity with $5.67M in cash and a 4.16x current ratio. Very low leverage with only $150K of long-term debt and 0.01x debt-to-equity.
What are the risks of investing in COEPW?
Claude: Extreme cash burn of $8.6M annually against only $1.4M revenue is unsustainable; ~8 months of cash runway remaining. Operating margin of -956.9% and net margin of -874.3% indicate massive losses with no near-term profitability path. ChatGPT: Severe operating inefficiency, with operating margin at -956.9% and net margin at -874.3%. Heavy cash burn, with operating cash flow and free cash flow both at -$8.60M.
What is COEPW's revenue and growth?
Coeptis Therapeutics Holdings, Inc. reported revenue of $1.4M.
Does COEPW pay dividends?
Coeptis Therapeutics Holdings, Inc. does not currently pay dividends.
Where can I find COEPW SEC filings?
Official SEC filings for Coeptis Therapeutics Holdings, Inc. (CIK: 0001759186) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COEPW's EPS?
Coeptis Therapeutics Holdings, Inc. has a diluted EPS of $-2.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is COEPW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Coeptis Therapeutics Holdings, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is COEPW stock overvalued or undervalued?
Valuation metrics for COEPW: ROE of -87.9% (sector avg: 12%), net margin of -874.3% (sector avg: 25%). Compare these metrics with sector averages to assess valuation.
Should I buy COEPW stock in 2026?
Our dual AI analysis gives Coeptis Therapeutics Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COEPW's free cash flow?
Coeptis Therapeutics Holdings, Inc.'s operating cash flow is $-8.6M, with capital expenditures of $0.0. FCF margin is -631.2%.
How does COEPW compare to other Finance stocks?
Vs Finance sector averages: Net margin -874.3% (avg: 25%), ROE -87.9% (avg: 12%), current ratio 4.16 (avg: 1.2).